histidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1377 71-00-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Histidine
  • histidine
An essential amino acid that is required for the production of HISTAMINE.
  • Molecular weight: 155.16
  • Formula: C6H9N3O2
  • CLOGP: -3.73
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 92
  • ALOGS: -0.40
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal growth restriction 93.79 87.08 15 82 7538 63481387

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:27027 trace elements
CHEBI has role CHEBI:50733 Dietary Supplement
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:75772 S. cerevisiae metabolites
CHEBI has role CHEBI:76971 Escherichia coli metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:84735 algal metabolites
CHEBI has role CHEBI:25212 metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Classical phenylketonuria contraindication 7573000
Poisoning by digitalis glycoside contraindication 12876009
Hypocupremia contraindication 19577007
Sarcoidosis contraindication 31541009 DOID:11335
End stage renal disease contraindication 46177005 DOID:784
Humoral hypercalcemia of malignancy contraindication 47709007
Heart disease contraindication 56265001 DOID:114
Hypercalcemia contraindication 66931009 DOID:12678
Ventricular fibrillation contraindication 71908006
Hypercalciuria contraindication 71938000
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.48 acidic
pKa2 13.85 acidic
pKa3 9.28 Basic
pKa4 6.6 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Large neutral amino acids transporter small subunit 1 Transporter IC50 4.70 CHEMBL

External reference:

IDSource
4018669 VUID
N0000146980 NUI
D00032 KEGG_DRUG
4018669 VANDF
C0019602 UMLSCUI
CHEBI:27570 CHEBI
HIS PDB_CHEM_ID
CHEMBL17962 ChEMBL_ID
DB00117 DRUGBANK_ID
D006639 MESH_DESCRIPTOR_UI
6274 PUBCHEM_CID
6163 INN_ID
3310 IUPHAR_LIGAND_ID
4QD397987E UNII
5340 RXNORM
NOCODE MMSL
004535 NDDF
60260004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ProcalAmine HUMAN PRESCRIPTION DRUG LABEL 22 0264-1915 INJECTION 0.09 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.48 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.48 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-1933 SOLUTION 0.48 g INTRAVENOUS NDA 23 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 894 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 894 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 894 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 894 mg INTRAVENOUS ANDA 20 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 894 mg INTRAVENOUS ANDA 20 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9010 INJECTION, SOLUTION 0.28 g INTRAVENOUS NDA 24 sections
FreAmine III HUMAN PRESCRIPTION DRUG LABEL 16 0264-9011 INJECTION, SOLUTION 0.28 g INTRAVENOUS NDA 24 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.48 g INTRAVENOUS NDA 23 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.29 g INTRAVENOUS NDA 23 sections
HepatAmine HUMAN PRESCRIPTION DRUG LABEL 16 0264-9371 INJECTION, SOLUTION 0.24 g INTRAVENOUS NDA 23 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0180 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0184 INJECTION, EMULSION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0188 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0194 INJECTION 384 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 288 mg INTRAVENOUS NDA 21 sections
CLINIMIX HUMAN PRESCRIPTION DRUG LABEL 16 0338-0198 INJECTION 288 mg INTRAVENOUS NDA 21 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 384 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 384 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0202 INJECTION 384 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 384 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 384 mg INTRAVENOUS NDA 20 sections
CLINIMIX E HUMAN PRESCRIPTION DRUG LABEL 21 0338-0206 INJECTION 384 mg INTRAVENOUS NDA 20 sections